Showing 7771-7780 of 8648 results for "".
- SIFI Reports Positive Results From 044/si Phase 3 Clinical Trial of Netildex Gelhttps://modernod.com/news/sifi-reports-positive-results-from-044-si-phase-3-clinical-trial-of-netildex-gel/2478196/SIFI has announced the conclusion of a phase 3 clinical trial aimed at demonstrating the noninferiority of Netildex gel administered twice daily (BID) vs. Netildex solution administered four ti
- Neuroptika Completes Enrollment In Phase 2 Clinical Trial For Dry Eye Diseasehttps://modernod.com/news/neuroptika-completes-enrollment-in-phase-2-clinical-trial-for-dry-eye-disease/2478192/Neuroptika announced completion of enrollment in a phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease. NRO-1 is a novel therapeutic with the potential to regenerate corneal nerves in ophthalmic diseases. “We are pleased to com
- FDA Grants EUA for Convalescent Plasma in Hospitalized COVID-19 Patientshttps://modernod.com/news/fda-grants-eua-for-convalescent-plasma-in-hospitalized-covid-19-patients/2478190/The FDA reversed itself Sunday following pressure from the White House and announced an Emergency Use Authorization for convalescent plasma as a treatment for patients who have contracted COVID-19, according to a BioSpace
- CDC Director Warns of Major Public Health Complications if Public Doesn’t Take Flu and COVID-19 Seriouslyhttps://modernod.com/news/cdc-director-warns-of-major-public-health-complications-if-public-doesnt-take-flu-and-covid-19-seriously/2478188/The Centers for Disease Control and Prevention (CDC) is scrambling to ensure there are enough supplies of—and public confidence in—the flu vaccine as fall approaches and COVID-19 is still spreading in the U.S, according to a FierceHealthcare
- Kubota Vision Receives Orphan Products Clinical Trial Grant for Stargardt Disease Treatment Candidatehttps://modernod.com/news/kubota-vision-receives-orphan-products-clinical-trials-grants-to-emixustat-for-stargardt-disease/2478187/Kubota Vision announced that the FDA Office of Orphan Products Development (OOPD) has awarded an orphan products clinical trial grant to support the ongoing phase 3 study of emixustat in Stargardt disease. Orphan product clinical trial grants support well-controlled studies that will eithe
- J&J Looking to Enroll 60,000 Participants in Coronavirus Vaccine Trialhttps://modernod.com/news/jj-looking-to-enroll-60000-participants-in-coronavirus-vaccine-trial/2478185/A phase 3 trial Johnson & Johnson is planning to get under way in September to test its coronavirus vaccine candidate Ad26.COV2.S is looking to recruit up to 60,000 participants globally, the company confirmed Thursday. The targeted enrollment, first reported on the ClinicalTrials.gov databas
- Medicare Spent $1.4B On Discarded Part B Drugs in 2017 and 2018: Reporthttps://modernod.com/news/medicare-spent-1-4b-on-discarded-part-b-drugs-in-2017-and-2018-report/2478186/A new report from MedicareAdvantage.com, an MA insurance broker, analyzed claims data from the Centers for Medicare & Medicaid Services (CMS) and found that Medicare spent $695 million on discarded Pa
- WSJ: Troubled COVID-19 Data System Returning to CDChttps://modernod.com/news/wsj-troubled-covid-19-data-system-returning-to-cdc/2478184/The U.S. Department of Health and Human Services is reversing course on a change to the way hospitals report critical information on the coronavirus pandemic to the government, returning the responsibility for data collection to the Centers for Disease Control and Prevention, according to a W
- LensGen Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directorshttps://modernod.com/news/lensgen-closes-10-million-financing-and-welcomes-james-v-mazzo-to-its-board-of-directors/2478182/LensGen announced the initial closing of a $10 million of the $20 million Bridge Financing and announcd the election of James Mazzo to its Board of Directors.
- Safer and More Effective Glaucoma Surgical Options Will Drive Surgery Device Treatment Penetration Over Next Five Yearshttps://modernod.com/news/safer-and-more-effective-glaucoma-surgical-options-will-drive-surgery-device-treatment-penetration-over-next-five-years/2478181/Expanding use of surgical devices in patients with all stages of glaucoma will increase the role of surgery in the glaucoma treatment paradigm over the next 5 years, according to a Market Scope report. There are four FDA-approved minimally invasive glaucoma surgery (MIGS) stents in the US: